Bionano Genomics, Inc. (BNGO)

0.8158 -0.0397 (-4.64%) At close: 04:00PM EDT

Bionano Genomics, Inc.

9540 Towne Centre Drive
Suite 100
San Diego, CA 92121
United States
858 888 7600
https://www.bionano.com

Sector(s): Healthcare
Industry: Medical Instruments & Supplies
Full Time Employees: 344

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Robert Erik Holmlin M.B.A., Ph.D.	President, CEO, Secretary & Director	834.57k	N/A	1968
Mr. Mark Oldakowski	Chief Operating Officer	603.82k	N/A	1974
Dr. Alka Chaubey FACMG, Ph.D.	Chief Medical Officer	558.83k	N/A	1973
Ms. Gulsen Kama M.B.A.	Chief Financial Officer	N/A	N/A	N/A
Mr. Mark Adamchak CPA	VP of Accounting & Controller	N/A	N/A	N/A
Mr. Jonathan Dixon J.D.	General Counsel	N/A	N/A	1975
Mr. Stanislas Marin M.B.A., M.S.	Vice President of Global Sales	N/A	N/A	N/A
Ms. Donna Polizio	Global Head of Market Access	N/A	N/A	N/A
Mr. Cory Kreeck	Global Head of People Operations	N/A	N/A	N/A
Dr. Klint Rose Ph.D.	Head of Research & Development	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Corporate Governance

Bionano Genomics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 10. The pillar scores are Audit: 9; Board: 7; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.